← Back to Bromantane

Bromantane Stats & Data

Ladasten Bromantan Adamantylbromphenylamine

NPS DataHub

MW306.25

FormulaC16H20BrN

CAS87913-26-6

IUPACN-(4-bromophenyl)adamantan-2-amine

SMILESBrc1ccc(cc1)NC1C2CC3CC(CC1C3)C2

InChIKeyLWJALJDRFBXHKX-UHFFFAOYSA-N

Psychoactive Class Stimulant

Half-Life ~11.5 h plasma (range 7–12 h) reported in secondary summaries; brain tissue distribution shorter (~7 h).

Pharmacology

DrugBank

Description

Bromantane/bromantan (Ladasten) is a drug developed in Russia in the 1980s. Derived from adamantane, bromantane is an actoprotector, which is a kind of drug that enhances physical activity under extreme environmental conditions (such as low oxygen or high temperature) 1, 2. Bromantane purportedly increases energy, reduces anxiety, inhibits fatigue, promotes learning, and improves movement coordination. All of these effects are claimed to combine to help increase both mental and physical performance. In Russia, bromantane is approved for the treatment of neurasthenia . It does not possess any addictive potential and has no serious side effects according to the limited scientific research . However, it is banned from many sports competitions, including the Olympics .

Receptor Profile

Receptor Actions

Agonists

Sigma-1 receptor agonist (putative)

Modulators

GABA-B receptor positive modulator

Other

Tyrosine hydroxylase upregulator

Aromatic L-amino acid decarboxylase upregulator

Effect Profile

Curated

Stimulant 9.1

Strong euphoria, focus, and stimulation with mild anxiety/jitters

Stimulation / Energy×3

Euphoria / Mood Lift×2

Focus / Productivity×2

Anxiety / Jitters×1

Based on reports from:

Erowid Experience Reports PsychonautWiki Bromantane

Tolerance & Pharmacokinetics

drugs.wiki

Half-Life

~11.5 h plasma (range 7–12 h) reported in secondary summaries; brain tissue distribution shorter (~7 h).

Addiction Potential

Low; available reviews and Russian clinical experience describe minimal classic dependence or withdrawal. Some users report transient dysphoria or fatigue upon abrupt cessation after weeks–months of daily use.

Tolerance Decay

Full tolerance 7d Half tolerance 7d Baseline ~60d

Anecdotal reports frequently describe rapid tachyphylaxis over 1–2 weeks of daily use, with partial reset after 2–8 weeks off. No controlled human tolerance studies located; values are heuristic and conservative for harm reduction. Consider limiting continuous runs and schedule breaks.

Cross-Tolerances

amantadine (adamantane dopaminergic)

30% ●○○

classic stimulants (amphetamine‑like)

20% ●○○

Legal Status

Country	Status	Notes
Germany	Bromantane is not a controlled substance under the BtMG ( Narcotics Act ) or the NpSG ( New Psychoactive Substances Act ).	According to §2 AMG ( Medicines Act ) it would fall under the definition of a medicine because it induces pharmacological effect. By a decision of the European Court of Justice, this definition was declared ineffective because it was not compatible with EU law. Bromantane can be considered legal.
Russia	In Russia Bromantane has been discontinued in 2017 and will not be available in the nearest future.
Switzerland	Bromantane is not controlled under Buchstabe A, B, C and D.	It could be considered legal.
United States	Bromantane is uncontrolled in the United States and has not been approved by the FDA for human use.	However, this has led nootropic vendor websites to sell bromantane under the label of "not for human consumption."

Harm Reduction

drugs.wiki

• Distinct from classic stimulants: clinical summaries emphasize activation without hyperstimulation and anxiolytic properties; this profile underlies its inclusion among actoprotectors and why some users feel it as “smooth” rather than jittery. However, experiences vary widely.

• World Anti‑Doping Agency prohibits bromantane (S6 stimulants); athletes risk sanctions and detection around competition periods.

• Take earlier in the day to reduce insomnia; evening doses and higher totals increase sleep disruption risk.

• Blood pressure and heart rate can rise—especially when combined with other stimulants or high caffeine—so avoid combos and monitor if you have hypertension.

• Reports suggest rapid tachyphylaxis in some users; cycling (e.g., limited 2–4 week runs followed by breaks) may mitigate tolerance.

• Some literature indicates induction of hepatic cytochrome P‑450 and reduced barbiturate hypnosis; this implies potential interactions (weaker effect of sedative‑hypnotics, altered clearance of co‑meds). Avoid mixing with anesthesia/sedatives without medical oversight.

• Anecdotes conflict on MAOI combinations; because bromantane increases dopaminergic tone, combining with MAOIs may unpredictably elevate catecholamines—treat as a do‑not‑mix unless a specialist is supervising.

• Product quality varies across vendors (different odors, inactive lots reported); pharmaceutical‑grade sources are rare outside Russia. Use caution, seek third‑party analysis when possible, and be skeptical of sudden formulation changes.

• Lipophilicity likely favors administration with dietary fat or oil for steadier effects; dry sublingual use is often reported as inconsistent.

• High single doses can become paradoxically flattening or fatiguing for some; titrate slowly and stop if you develop apathy or headache.

• People with bipolar spectrum, psychosis history, uncontrolled hypertension, significant liver disease, or pregnancy/breastfeeding should avoid non‑medical use due to unknowns and potential risk amplification.